GlassScriptPhysician profile
Howard N Kivell
NPI 1619088598
$2,304.15
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,926 · 2020: $378.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $330.00 | 2019-2020 | |
| Janssen Biotech, INC. | $260.59 | 2019-2020 | |
| Pfizer INC. | $221.38 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $198.90 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $194.49 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $182.58 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $165.28 | 2019-2020 | |
| Allergan, INC. | $156.74 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $128.40 | 2019-2020 | |
| Blue Earth Diagnostics | $101.34 | 2019 | |
| Dendreon Pharmaceuticals LLC | $76.64 | 2019 | |
| Neotract INC. | $55.70 | 2019 | |
| Abbvie INC. | $50.31 | 2019 | |
| Dentsply Ih INC. | $45.44 | 2019-2020 | |
| Amgen INC. | $45.12 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $34.61 | 2020 | |
| 180 Medical, INC. | $19.81 | 2019 | |
| Coloplast Corp | $12.93 | 2019 | |
| Rochester Medical Corporation | $12.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Kivell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.